What would Metsera bring to Novo Nordisk?news2025-10-31T11:32:14+00:00October 31st, 2025|Endpoints News|
Vesper Bio reports early biomarker data for neurodegenerative disease candidatenews2025-10-31T10:57:21+00:00October 31st, 2025|Endpoints News|
Lilly CEO expects more ‘noise’ as Metsera M&A fight beginsnews2025-10-30T19:32:53+00:00October 30th, 2025|Endpoints News|
Bristol Myers Q3 earnings: Cobenfy anxiety, PD-1xVEGF strategy and MFNnews2025-10-30T15:34:04+00:00October 30th, 2025|Endpoints News|
Tectonic shares rise on back of Phase 1 heart failure datanews2025-10-30T15:18:52+00:00October 30th, 2025|Endpoints News|
Wave Life Sciences’ obesity biomarker data raise hopes for future readoutsnews2025-10-30T11:13:11+00:00October 30th, 2025|Endpoints News|
Takeda makes some pipeline cuts, says generic competition softened sales over last six monthsnews2025-10-30T11:09:35+00:00October 30th, 2025|Endpoints News|
Ventus stops Phase 2 of NLRP3 inhibitor that was being tested in Parkinson’snews2025-10-29T17:05:59+00:00October 29th, 2025|Endpoints News|
FDA to reduce regulatory red tape for biosimilarsnews2025-10-29T16:43:48+00:00October 29th, 2025|Endpoints News|
After this year’s Nobel Prize, the first results for a CAR-Treg for autoimmune disease are innews2025-10-29T15:31:04+00:00October 29th, 2025|Endpoints News|
